Core Viewpoint - The announcement reveals a significant change in the ownership structure of Hehua Co., Ltd. (河化股份), with the controlling shareholder shifting from Ningbo Yinyi Holdings Co., Ltd. to Ningbo Zhongzhe Ruihe Enterprise Management Consulting Co., Ltd. This transaction involves the transfer of 87 million shares, representing 23.76% of the total share capital, for a total consideration of 632 million yuan [1]. Group 1: Ownership Change - Ningbo Yinyi Holdings plans to transfer 87 million shares and all receivables from Hehua Co. to Zhongzhe Ruihe for a total price of 632 million yuan [1]. - If the transaction is completed, the controlling shareholder will change to Zhongzhe Ruihe, and the actual controller will change from Xiong Xuqiang to Yang Herong [1]. - Zhongzhe Ruihe was established in July 2025 and is wholly owned by Zhongzhe Group, focusing on enterprise management consulting and financial consulting [1]. Group 2: Company Performance - In the first half of 2025, Hehua Co. reported revenue of 80.83 million yuan, a decrease of 37.02% year-on-year, while net profit attributable to shareholders increased by 45.56% to 3.84 million yuan [3]. - The revenue decline was attributed to management optimization and resource allocation, which improved per capita output, as well as the recovery of previously written-off bad debts [3]. - The company's subsidiary, Nansong Pharmaceutical, reported revenue of 42.67 million yuan, down 31.52%, while Hehua Biological reported revenue of 38.10 million yuan, down 42.28% [3]. Group 3: Business Overview - Hehua Co. primarily engages in the research, production, and sales of pharmaceutical intermediates and urea processing and sales [2]. - Its subsidiary, Nansong Pharmaceutical, specializes in pharmaceutical intermediates, with products sold domestically and to markets such as Taiwan, India, and Finland [2]. - Hehua Biological leverages its established reputation in urea sales and operates through third-party processing [2].

7月30日晚间，河化股份（000953）公告，公司近日收到控股股东宁波银亿控股有限公司的通知，其正 在筹划股权转让相关事宜，该事项可能导致公司控股股东及实际控制人发生变更，目前各方尚未签署相 关正式交易协议，拟就相关事项进行进一步论证和磋商，具体情况以各方签订的相关正式交易协议为 准。 公告显示，鉴于该事项正在筹划中，具有较大不确定性。为保证公平信息披露，维护投资者利益，避免 造成河化股份股价异常波动，根据深交所有关规定，经公司向深圳证券交易所申请，公司股票自2025年 7月31日上午开市起停牌，预计停牌时间不超过2个交易日。 河化股份还提到，公司将继续加大对主营业务企业南松医药战略转型的支持力度，充分调动一切资源， 为企业产品开发和市场拓展提供帮助。同时，克服尿素市场行情波动大，公司尿素品牌效应降低的不利 因素影响，继续开展尿素委托加工及销售业务，维护"群山"品牌和经销商网络。此外，公司将进一步健 全安全消防环保管理体系，牢固树立安全无小事理念，定期组织开展安全、消防、环保等各类培训，加 强监督管理，有效杜绝生产安全事故的发生。 截至今年一季度末的数据显示，河化股份第一大股东为宁波银亿控股有限公司，持股比例 ...